Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.

@article{Posselt2010IsletTI,
  title={Islet transplantation in type 1 diabetics using an immunosuppressive protocol based on the anti-LFA-1 antibody efalizumab.},
  author={Andrew Mark Posselt and Melena D Bellin and Mehdi Tavakol and Gregory L. Szot and Lynda Ann Frassetto and U. Masharani and Robert K. Kerlan and Lawrence Fong and Flavio G. Vincenti and Bernhard J. Hering and Jeffrey A Bluestone and Peter G. Stock},
  journal={American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons},
  year={2010},
  volume={10 8},
  pages={1870-80}
}
The applicability of islet transplantation as treatment for type 1 diabetes is limited by renal and islet toxicities of currently available immunosuppressants. We describe a novel immunosuppressive regimen using the antileukocyte functional antigen-1 antibody efalizumab which permits long-term islet allograft survival while reducing the need for corticosteroids and calcineurin inhibitors (CNI). Eight patients with type 1 diabetes and hypoglycemic unawareness received intraportal allogeneic… CONTINUE READING